Charcot-Marie-Tooth disease type 1A with 17p11. 2 duplication. Clinical and electrophysiological phenotype study and factors influencing disease severity in 119 …
N Birouk, R Gouider, E Le Guern… - Brain: a journal of …, 1997 - academic.oup.com
A clinical and electrophysiological study was performed in 119 Type 1A Charcot-Marie-Tooth
disease (CMT1A) patients with proven 17p11.2 duplication. Onset of the first functional …
disease (CMT1A) patients with proven 17p11.2 duplication. Onset of the first functional …
[HTML][HTML] Reducing the risk of cognitive decline and dementia: WHO recommendations
…, A Bibi Mia Sorefan, A Dias, R Gouider… - Frontiers in …, 2022 - frontiersin.org
With population ageing worldwide, dementia poses one of the greatest global challenges for
health and social care in the 21st century. In 2019, around 55 million people were affected …
health and social care in the 21st century. In 2019, around 55 million people were affected …
Diagnosis and classification of optic neuritis
…, CF Tilikete, K Fujihara, A Gálvez, R Gouider… - The Lancet …, 2022 - thelancet.com
There is no consensus regarding the classification of optic neuritis, and precise diagnostic
criteria are not available. This reality means that the diagnosis of disorders that have optic …
criteria are not available. This reality means that the diagnosis of disorders that have optic …
Characterization of recessive Parkinson disease in a large multicenter study
…, B Bilgic, M Tazir, MB Djebara, R Gouider… - Annals of …, 2020 - Wiley Online Library
Studies of the phenotype and population distribution of rare genetic forms of parkinsonism
are required, now that gene‐targeting approaches for Parkinson disease have reached the …
are required, now that gene‐targeting approaches for Parkinson disease have reached the …
Comparative effectiveness of autologous hematopoietic stem cell transplant vs fingolimod, natalizumab, and ocrelizumab in highly active relapsing-remitting multiple …
…, D Spitaleri, T Csepany, R Gouider… - JAMA …, 2023 - jamanetwork.com
Importance Autologous hematopoietic stem cell transplant (AHSCT) is available for treatment
of highly active multiple sclerosis (MS). Objective To compare the effectiveness of AHSCT …
of highly active multiple sclerosis (MS). Objective To compare the effectiveness of AHSCT …
[HTML][HTML] Characteristics, onset, and evolution of neurological symptoms in patients with COVID-19
…, A Gargouri, M Chahed, N Ben Alaya, R Gouider - Neurological …, 2021 - Springer
Background A wide range of neurological manifestations has been described in COVID-19.
Methods In this nationwide retrospective observational study, patients in Tunisia diagnosed …
Methods In this nationwide retrospective observational study, patients in Tunisia diagnosed …
The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and …
…, KC Fitzgerald, M Fonderico, R Gouider… - Multiple Sclerosis …, 2022 - journals.sagepub.com
Over the recent years, the treatment of multiple sclerosis (MS) and neuromyelitis optica
spectrum disorder (NMOSD) has evolved very rapidly and a large number of disease-modifying …
spectrum disorder (NMOSD) has evolved very rapidly and a large number of disease-modifying …
Unverricht‐Lundborg disease
…, S Franceschetti, P Genton, R Gouider… - Epileptic …, 2016 - Wiley Online Library
We first review the clinical presentation and current therapeutic approaches available for
treating Unverricht‐Lundborg disease (ULD), a progressive myoclonus epilepsy. Next, we …
treating Unverricht‐Lundborg disease (ULD), a progressive myoclonus epilepsy. Next, we …
Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression
…, C Oreja-Guevara, D Maimone, R Gouider… - Computer methods and …, 2021 - Elsevier
Background and Objectives Research in Multiple Sclerosis (MS) has recently focused on
extracting knowledge from real-world clinical data sources. This type of data is more abundant …
extracting knowledge from real-world clinical data sources. This type of data is more abundant …
Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial
…, J Meca-Lallana, CC Triki, M Chokri, R Gouider… - The Lancet …, 2021 - thelancet.com
Background Therapeutic options for children with multiple sclerosis are scarce. Teriflunomide
is approved in more than 80 countries for the treatment of adults with relapsing multiple …
is approved in more than 80 countries for the treatment of adults with relapsing multiple …